Search
Xylitol
go.drugbank.com/drugs/DB11195ApprovedInvestigationalThe recommended dose of xylitol for dental caries prevention is 6–10 g/day, and most adults can tolerate 40 g/day without adverse events [A22081]. … It is widely used as a sugar substitute and in "sugar-free" food products.
Mixtures: Fluor-a-day, Fluor-a-dayCategories: Compounds used in a research, industrial, or household settingAvibactam
go.drugbank.com/drugs/DB09060ApprovedInvestigationalAvibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). … As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options.
Products: ZAVICEFTA POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 2G/0.5GSutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigationalSutimlimab is a first-in-class humanized monoclonal antibody targeted at complement subunit C1s, which is responsible for activating the classic complement pathway. … [A245159] Treatment options for patients with CAD are limited.
Acetyl sulfisoxazole
go.drugbank.com/drugs/DB14033ApprovedVet approvedSulfisoxazole acetyl is an ester of _sulfisoxazole_, a broad-spectrum sulfanilamide and a synthetic analog of para-aminobenzoic acid (PABA) with antibacterial activity. … Sulfisoxazole acetyl competes with PABA for the bacterial enzyme, _dihydropteroate synthase_, preventing the incorporation of PABA into dihydrofolic acid, which is the precursor of folic acid.
Semaglutide
go.drugbank.com/drugs/DB13928ApprovedInvestigational[L8678] The subcutaneous injection is administered once weekly and the tablet is administered once a day. … as the first approved drug for such use since 2014.
Products: OZEMPIC 1MG/DOSE SOLUTION FOR INJECTION IN PRE-FILLED PEN 1.34MG/ML, OZEMPIC 0.25MG, 0.5MG/DOSE SOLUTION FOR INJECTION IN PRE-FILLED PEN 1.34MG/MLMemantine
go.drugbank.com/drugs/DB01043ApprovedInvestigationalIn December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or a disease-modifying therapy by the year 2025 [L5953, F4366 … Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease [T556].
Products: MEMANTIN 1A PHARMA 10MG, MEMANTIN 1A PHARMA 20MGSalsalate
go.drugbank.com/drugs/DB01399ApprovedInvestigationalSalsalate is a nonsteroidal anti-inflammatory agent for oral administration. … Such capacity limited biotransformation results in an increase in the half-life of salicylic acid from 3.5 to 16 or more hours.
Birch bark extract
go.drugbank.com/drugs/DB16536ApprovedInvestigational[L42365,L42370] Filsuvez, one of these two formulations, is approved for the treatment of partial thickness wounds in patients with epidermolysis bullosa (EB), a rare group of hereditary disorders of the … [L42390] Filsuvez was subsequently approved for the same indication by the US FDA in December 2023.
Cenobamate
go.drugbank.com/drugs/DB06119ApprovedInvestigationalCenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures. … [A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABA<sub>A</sub> and inhibits voltage gated sodium channels.
Ceftizoxime
go.drugbank.com/drugs/DB01332ApprovedWithdrawnA semisynthetic cephalosporin antibiotic which can be administered intravenously or by suppository. … The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative organisms.
Categories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use